ANAB - ANAPTYSBIO, INC

QQQ $ 617.50 $ 6.52 (1.07 %)

DIA $ 472.45 $ 4.92 (1.05 %)

SPY $ 677.25 $ 5.49 (0.82 %)

TLT $ 91.47 $ 0.04 (0.04 %)

GLD $ 378.59 $ -1.27 (-0.34 %)

Previous Close

$ 35.07

Open

$ 34.14

Bid

$ 33.00 x 500

Ask

$ 35.74 x 30

Day's Range

$ 34.05 - $ 35.15

52 Week Range

$ 12.21 - $ 35.77

Volume

198,201

Average Volume

Market Cap

981.85M

Beta (5Y Monthly)

$ 0.54

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	08-06-2025	06-30-2025	10-Q
2	05-05-2025	03-31-2025	10-Q
3	02-27-2025	01-01-1970	10-K
4	11-05-2024	09-30-2024	10-Q
5	08-05-2024	06-30-2024	10-Q
6	05-09-2024	03-31-2024	10-Q
7	03-11-2024	12-31-2023	10-K
8	11-02-2023	09-30-2023	10-Q
9	08-07-2023	06-30-2023	10-Q
10	05-11-2023	03-31-2023	10-Q
11	03-01-2023	12-31-2022	10-K
12	11-08-2022	09-30-2022	10-Q
13	08-08-2022	06-30-2022	10-Q
14	05-04-2022	03-31-2022	10-Q
15	03-07-2022	12-31-2021	10-K
16	11-04-2021	09-30-2021	10-Q
17	08-09-2021	06-30-2021	10-Q
18	05-04-2021	03-31-2021	10-Q
19	02-25-2021	12-31-2020	10-K
20	11-04-2020	09-30-2020	10-Q
21	08-10-2020	06-30-2020	10-Q
22	05-06-2020	03-31-2020	10-Q
23	03-02-2020	12-31-2019	10-K
24	11-08-2019	09-30-2019	10-Q
25	08-08-2019	06-30-2019	10-Q
26	05-07-2019	03-31-2019	10-Q
27	02-28-2019	12-31-2018	10-K
28	11-08-2018	09-30-2018	10-Q
29	08-07-2018	06-30-2018	10-Q
30	05-08-2018	03-31-2018	10-Q
31	03-05-2018	12-31-2017	10-K
32	11-07-2017	09-30-2017	10-Q
33	08-10-2017	06-30-2017	10-Q
34	05-12-2017	03-31-2017	10-Q
35	03-08-2017	12-31-2016	10-K

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

Wedbush Maintains Outperform on AnaptysBio...
10/15/2025 15:11:02

Wedbush analyst David Nierengarten maintains AnaptysBio (NASDAQ:ANAB) with a Outperform and raises the price target from $45...

AnaptysBio Says Complete Data From Phase 2...
10/13/2025 13:18:04

AnaptysBio, Inc. (NASDAQ:ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics...

Barclays Initiates Coverage On AnaptysBio ...
10/13/2025 12:02:06

Barclays analyst Etzer Darout initiates coverage on AnaptysBio (NASDAQ:ANAB) with a Overweight rating and announces Price Ta...

anaptysbio-charts-path-to-split-into-two-public-companies-by-2026

AnaptysBio Charts Path To Split Into Two P...
09/30/2025 17:59:14

AnaptysBio plans to separate into Royalty Management Co. and Biopharma Co. by 2026, with each positioned for growth in distinct...

12 Health Care Stocks Moving In Tuesday's ...
09/30/2025 17:06:34

united-natural-foods-posts-upbeat-results-joins-anaptysbio-semtech-uipath-and-other-big-stocks-moving-higher-on-tuesday

United Natural Foods Posts Upbeat Results,...
09/30/2025 15:06:57

Wedbush Reiterates Outperform on AnaptysBi...
09/30/2025 12:57:13

Wedbush analyst Martin Fan reiterates AnaptysBio (NASDAQ:ANAB) with a Outperform and maintains $45 price target.

HC Wainwright & Co. Maintains Buy on Anapt...
09/30/2025 11:38:00

HC Wainwright & Co. analyst Emily Bodnar maintains AnaptysBio (NASDAQ:ANAB) with a Buy and raises the price target from ...

12 Health Care Stocks Moving In Monday's A...
09/29/2025 21:06:06

Gainers SciSparc (NASDAQ: SPRC) shares increased by 28.2% to $5.68 during Monday's after-market session. The company's...

Trading Halt: Halt status updated at 4:30:...
09/29/2025 20:30:10

AnaptysBio To Host Investor Event On ANB03...
09/29/2025 20:13:37

AnaptysBio, Inc. (NASDAQ: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutic...

AnaptysBio Intends To Separate Biopharma B...
09/29/2025 20:09:56

Designed to unlock potential value by creating two independent, publicly traded companies with different business objectives an...

Trading Halt: Halted at 4:00:10 p.m. ET - ...
09/29/2025 20:00:25

UBS Maintains Neutral on AnaptysBio, Raise...
08/12/2025 13:38:22

UBS analyst Eliana Merle maintains AnaptysBio (NASDAQ:ANAB) with a Neutral and raises the price target from $18 to $20.

Analyst Expectations For AnaptysBio's Future
08/07/2025 13:02:05

Wedbush Maintains Outperform on AnaptysBio...
08/07/2025 12:45:57

Wedbush analyst Martin Fan maintains AnaptysBio (NASDAQ:ANAB) with a Outperform and raises the price target from $40 to $45.

AnaptysBio Q2 EPS $(1.34) Beats $(1.52) Es...
08/06/2025 21:07:59

AnaptysBio (NASDAQ:ANAB) reported quarterly losses of $(1.34) per share which beat the analyst consensus estimate of $(1.52) by...

Analyst Expectations For AnaptysBio's Future
07/24/2025 18:00:21

JP Morgan Maintains Overweight on AnaptysB...
07/24/2025 14:13:25

JP Morgan analyst Anupam Rama maintains AnaptysBio (NASDAQ:ANAB) with a Overweight and raises the price target from $42 to $80.

anaptysbios-arthritis-drug-matches-top-therapies-in-phase-2-trial-analyst-sees-turning-point

AnaptysBio's Arthritis Drug Matches Top Th...
06/04/2025 18:23:16

Rosnilimab met key RA trial goals, with sustained clinical responses and safety benefits, prompting an analyst upgrade and pric...